OakChart

CapsoVision Inc

CVHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 3:59 PM ET

6.27-0.10 (-1.57%)
2026-11-12 04:25 CET
Market cap
333.63 USD m
Revenue, TTM
13.89 USD m
Net income, TTM
-29.83 USD m
Free cash flow, TTM
-27.89 USD m
EPS diluted, TTM
-0.62
P/E
-
Compare

Price

CV against its 20, 50 and 200-day averages
2050200missearnings
5.506.006.507.007.50828K1.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CVclose 6.2720-day 6.6650-day 6.52200-day 6.376.27

59.2% under the 52-week high of 15.37 on 11 Dec 2025. 52-week low 4.50 on 20 Feb 2026. Last 15 sessions, 18.2% high to low

Volume 0.35× normal · the line is the 50-bar volume average

Profile

CV
52-week range, 16% of the way up
4.5015.37

CapsoVision, Inc. operates as a commercial-stage medical technology company. It engages in the development of imaging and artificial intelligence (AI) technologies that are deployed for endoscopy solutions to identify abnormalities of the gastrointestinal (GI) tract for diagnostic and screening purposes. The firm developed capsule endoscope system, currently comprising the CapsoCam Plus single-use capsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease. The company was founded by Kang-Huai Wang on August 1, 2005 and is headquartered in Saratoga, CA.

IndexRUT
Employees99
IPOJul 02, 2025
Beta-2.15
ATR, 14d0.34
Rel volume0.35
Short float7.25%
Insider own49.45%
Inst own10.31%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap333.63M
Enterprise Value325.24M
Income-29.83M
Sales13.89M
Book/sh0.26
Cash/sh0.17
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees99
IPOJul 02, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S24.02
P/B23.83
P/C36.74
P/FCF-
EV/EBITDA-
EV/Sales23.42
Quick Ratio2.44
Current Ratio3.35
Debt/Eq0.05
LT Debt/Eq0.02
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.62
EPS next Y-0.45
EPS next Q-0.15
EPS this Y45.63%
EPS next Y19.64%
EPS next 5Y48.58%
EPS past 3/5Y-48.82% -
Sales past 3/5Y17.89% -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-51.47%
Sales Q/Q9.89%
EarningsNov 12 AMC
EPS/Sales Surpr.-15.38% -4.46%

Ownership

Insider Own49.45%
Insider Trans11.87%
Inst Own10.31%
Inst Trans10.96%
ROA-212.19%
ROE-335.06%
ROIC-222.42%
Gross Margin50.88%
Oper. Margin-217.14%
Profit Margin-214.74%
SMA20-5.91%
SMA50-3.79%
SMA200-1.59%
Trades-

Technical

Shs Outstand50.03M
Shs Float26.90M
Short Float7.25%
Short Ratio11.70
Short Interest1.95M
52W High15.37 -59.21%
52W Low4.50 39.33%
Volatility6.20% 4.98%
ATR (14)0.34
RSI (14)42.25
Beta-2.15
Rel Volume0.35
Avg Volume166.72K
Volume58,572

Performance

Perf Week-8.47%
Perf Month-7.52%
Perf Quarter-7.66%
Perf Half Y-10.43%
Perf YTD-41.35%
Perf Year15.15%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price9.67
Prev Close6.37
Price6.27
Change %-1.57%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Aug 28, 2026ResumedRRoth CapitalBuy$9+43.5%
Jul 28, 2025InitiatedTThe Benchmark CompanySpeculative Buy$5-20.3%
Jul 28, 2025InitiatedRRoth CapitalBuy$6-4.3%

Peers

Mkt cap
TickerCompanyMkt cap
MDTMedtronic Plc129.98B
BFLYButterfly Network Inc1.91B
LUCDLucid Diagnostics Inc77.52M
HYPRHyperfine Inc75.43M
MBOTMicrobot Medical Inc74.55M
NNOXNano X Imaging Ltd28.66M
SSIISS Innovations International Inc302.72M
PRCTProcept BioRobotics Corp1.34B
OWLTOwlet Inc134.42M
STXSStereotaxis Inc90.18M

Insider trading

latest 14 of 19
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
HARARI ELIYAHOU ET AL10% OwnerSep 18 '26Buy5.691,757,4699,999,9991,396,494Sep 23 09:01 PM
Shen Ching Hang10% OwnerSep 15 '26Buy5.69878,7344,999,9962,926,655Sep 18 06:14 PM
HARARI ELIYAHOU ET AL10% OwnerJul 17 '26Buy6.7361,068410,9883,343,119Jul 21 07:04 PM
HARARI ELIYAHOU ET AL10% OwnerJul 08 '26Buy6.0981,300495,1173,282,051Jul 10 08:17 PM
HARARI ELIYAHOU ET AL10% OwnerJun 26 '26Buy7.3513,850101,8113,200,751Jul 07 10:03 PM
Imperial Joanne CarolDirectorJun 30 '26Option Exercise7.582,02215,3273,709Jul 01 09:22 PM
Tsai Chen LungDirectorJun 30 '26Option Exercise7.582,02215,3274,929Jul 01 08:19 PM
Kuo Hui YingDirectorJun 30 '26Option Exercise7.582,02215,32715,263Jul 01 08:18 PM
King Wen-Herng HenryDirectorJun 30 '26Option Exercise7.582,02215,32725,619Jul 01 08:18 PM
Harari MicheleDirectorJun 30 '26Option Exercise7.582,02215,32761,065Jul 01 08:18 PM
GOUW JULIA SDirectorJun 30 '26Option Exercise7.582,02215,3274,909Jul 01 08:17 PM
Atkinson Douglas PatrickHead of Global SalesMay 04 '26Option Exercise0.3472,57125,00072,571May 06 12:50 PM
Atkinson Douglas PatrickHead of Global SalesMay 05 '26Option Exercise0.5734,78619,692107,357May 06 12:50 PM
Harari MicheleDirectorDec 31 '25Option Exercise10.692,88730,86259,043Dec 31 05:11 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B
VTHRVanguard Russell 3000 Index ETFAUM: 4.81B
ITWOProShares Russell 2000 High Income ETFAUM: 178.20M

News

latest 14 of 68
  • CapsoVision's FDA Verdict On US AI Highlights Looms Over A Modest Growth Quarter (Earnings Whispers) -9.49%
  • CapsoVision to Release Third Quarter 2026 Financial Results on November 12, 2026 (GlobeNewswire)
  • CapsoVision to Present at the 20th Annual LD Micro Main Event (GlobeNewswire)
  • CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus (GlobeNewswire)
  • CapsoVision to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • CapsoVision Inc (CV) (Q2 2026) Earnings Call Highlights: AI Launch Drives Growth Amid Pricing ... (GuruFocus.com)
  • CapsoVision Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • CapsoVision Announces International Launch of AI Highlights (GlobeNewswire) +8.97%
  • CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026 (GlobeNewswire)
  • Visteon Announces Second Quarter 2026 Financial Results and $200 Million Accelerated Share Repurchase Program (PR Newswire)
  • CapsoVision Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors (GlobeNewswire) -9.20%
  • CapsoVision Reports First Quarter 2026 Financial Results (GlobeNewswire) -11.58%
  • CapsoVision to Release First Quarter 2026 Financial Results on May 14, 2026 (GlobeNewswire) +10.62% +5.93%
  • These 16 stocks are a short seller's dream - likely losers no matter what the market does (MarketWatch)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.147--3.743
2026Q22026-08-13-0.150-0.130-0.1503.643.811
2026Q12026-05-14-0.150-0.130-0.1482.792.981
2025Q42026-03-26-0.160-0.145-0.1583.904.152
2025Q32025-11-13-0.170-0.124-0.1693.543.672
2025Q22025-08-14-2.020-0.110-0.0993.323.252
2025Q12025-05-28-1.310--0.1162.79--
2026Q4---0.117--4.563
2027Q1---0.127--3.663
2027Q2---0.117--4.583
2027Q3---0.113--4.773
2027Q4---0.097--6.233

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-1.030-1.020-1.03013.5513.82
2026FY--0.560--14.78
2027FY--0.450--19.28
2028FY--0.140--41.00
2029FY-0.290--89.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-283003.743.703.80
2026Q3S2026-08-273013.743.703.80
2026Q3S2026-08-252013.713.703.72
2026Q3S2026-08-141013.723.723.72
2026Q3S2026-08-131004.124.124.12
2026Q3S2026-06-101004.124.124.12
2026Q3S2026-05-151014.124.124.12
2026Q3S2026-05-061014.124.124.12
2026Q3S2026-03-272014.114.104.12
2026Q3S2026-01-282004.334.104.57
2026Q3S2025-11-142014.334.104.57
2026Q3S2025-11-112005.554.576.52
2026Q3S2025-11-102005.554.576.52
2026Q3S2025-11-092005.554.576.52

Estimate history

EPS, annual-0.244-0.429-0.54-0.625
Period202320242025TTM
EPS, quarterly-0.091-0.125-0.116-0.099-0.169-0.158-0.148-0.15
PeriodQ1 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual9.75311.75613.55413.89
Period202320242025TTM
Sales, quarterly2.4952.9662.7833.3153.5383.9182.7923.643
PeriodQ1 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual46.34446.34446.86550.032
Period202320242025MRQ
Shares, quarterly46.34446.34446.34446.77446.79946.86549.83950.032
PeriodQ1 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue13.8913.5511.769.75
Cost of Goods Sold Incl. D&A6.826.385.384.26
Gross Profit7.077.176.385.49
Selling, General and Administrative Excl. Other37.2332.5026.3916.71
Research and Development21.5518.3115.129.33
Other Operating Expense0.000.000.000.00
Operating Income-30.16-25.32-20.01-11.22
Interest Expense0.000.000.000.00
Unusual Expense0.020.00-0.090.13
Net Income Before Taxes-29.80-25.29-19.89-11.29
Income Taxes0.020.020.010.01
Consolidated Net Income-29.83-25.32-19.90-11.30
Net Income From Continuing Operations-29.83-25.32-19.90-11.30
Net Income-29.83-25.32-19.90-11.30
EPS (Recurring)-0.60-0.54-0.43-0.24
EPS (Basic, Before Extraordinaries)-0.62-0.54-0.43-0.24
EPS (Diluted)-0.62-0.54-0.43-0.24
EBITDA-29.57-24.76-19.49-10.83
Non-Operating Income (Expense)0.380.030.030.05
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense1.230.650.120.03
Price To Sales Ratio27.2536.96--
Gross Margin50.8852.9254.2456.30
Operating Margin-217.14-186.83-170.21-115.05
Net Margin-214.74-186.77-169.26-115.91
Shares Outstanding50.0346.8746.3446.34
Market Capitalization333.63333.63580.39-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q32024Q1
Total Revenue3.642.793.923.543.312.782.972.50
Cost of Goods Sold Incl. D&A1.771.461.961.621.501.291.311.10
Gross Profit1.871.331.951.911.811.491.661.39
Selling, General and Administrative Excl. Other9.478.439.429.916.296.887.435.61
Research and Development5.314.435.726.093.393.114.523.26
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.60-7.10-7.46-8.00-4.47-5.39-5.77-4.22
Interest Expense0.000.000.000.000.010.000.000.00
Unusual Expense0.000.000.000.020.18-0.010.03-0.01
Net Income Before Taxes-7.48-7.03-7.37-7.92-4.62-5.38-5.79-4.20
Income Taxes0.000.000.020.000.000.000.000.00
Consolidated Net Income-7.48-7.03-7.39-7.92-4.62-5.38-5.79-4.20
Net Income From Continuing Operations-7.48-7.03-7.39-7.92-4.62-5.38-5.79-4.20
Net Income-7.48-7.03-7.39-7.92-4.62-5.38-5.79-4.20
EPS (Recurring)-0.15-0.15-0.16-0.17-0.10-0.12-0.12-0.09
EPS (Basic, Before Extraordinaries)-0.15-0.15-0.16-0.17-0.10-0.12-0.12-0.09
EPS (Diluted)-0.15-0.15-0.16-0.17-0.10-0.12-0.12-0.09
EBITDA-7.45-6.95-7.32-7.86-4.33-5.25-5.64-4.09
Non-Operating Income (Expense)0.120.070.090.100.040.010.010.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.560.330.020.310.170.120.010.01
Price To Sales Ratio27.2525.5136.96-----
Gross Margin51.3647.6049.8754.1054.6353.6855.8755.87
Operating Margin-208.67-254.30-190.45-226.09-134.96-193.60-194.54-169.02
Net Margin-205.35-251.90-188.72-223.88-139.52-193.14-195.35-168.34
Shares Outstanding50.0349.8446.8746.8046.7746.3446.3446.34
Market Capitalization333.63363.32500.75226.39211.89---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments10.119.3214.56
Short Term Receivables2.502.001.87
Inventories2.992.632.19
Other Current Assets1.070.670.58
Total Current Assets16.6714.6219.20
Net Property, Plant & Equipment1.451.922.28
Total Investments and Advances0.000.000.00
Deferred Tax Assets0.38--
Other Assets0.040.270.04
Total Assets18.5416.8021.53
Short Term Debt Incl. Current Port. of LT Debt0.410.350.28
Accounts Payable1.140.750.36
Other Current Liabilities2.870.700.87
Total Current Liabilities4.431.801.51
Long Term Debt0.480.891.24
Provision for Risks Charges0.000.000.00
Deferred Tax Liabilities0.38--
Other Liabilities0.000.000.00
Total Liabilities5.282.692.75
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.00143.62128.62
Common Equity13.26-129.51-109.84
Total Shareholders Equity13.2614.1218.78
Accumulated Minority Interest0.000.000.00
Total Equity13.2614.1218.78
Total Liabilities & Stockholders Equity18.5416.8021.53
Book Value Per Share0.28-2.79-2.37
Tangible Book Value Per Share0.28-2.79-2.37
Full-Time Employees99--
Price to Book Ratio23.8328.36-
Return on Assets-143.26-103.83-
Return on Equity-184.95-120.97-
Return on Invested Capital-184.28-132.64-56.47
Quick Ratio3.096.6611.28
Current Ratio3.778.1212.74

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income-29.83-25.32-19.90-11.30
Depreciation0.590.570.520.39
Other Funds (Non Cash)1.450.700.27-0.05
Funds from Operations-27.79-24.05-19.11-10.96
Extraordinary Item0.000.000.000.00
Changes in Working Capital-0.031.19-0.980.16
Cash from Operating Activities-27.82-22.86-20.09-10.80
Capital Expenditures-0.07-0.09-0.15-0.75
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments0.000.000.000.00
Purchase of Investments0.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.00
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities-0.07-0.09-0.15-0.75
Cash Dividends Paid-0.010.000.000.00
Change in Capital Stock36.9223.6015.0720.53
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock36.9223.6015.0720.53
Proceedsfrom Stock Options36.7723.3715.0020.35
Issuance or Reduction of Debt, Net-1.000.000.000.00
Change in Long Term Debt0.000.000.000.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00
Other Financing Activities Uses0.000.000.000.00
Cash from Financing Activities35.9123.6015.0720.53
Exchange Rate Effect0.240.140.07-0.04
Net Change in Cash8.270.79-5.108.93
Free Cash Flow-27.89-22.95-20.24-11.56
Preferred Dividends (Cash Flow)-0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments9.0817.9310.1117.791.074.40
Short Term Receivables2.271.932.501.871.851.64
Inventories4.703.492.993.193.043.04
Other Current Assets1.231.061.071.200.700.64
Total Current Assets17.2824.4116.6724.056.669.71
Net Property, Plant & Equipment1.211.371.451.571.711.82
Total Investments and Advances0.000.000.000.000.000.00
Deferred Tax Assets--0.38---
Other Assets0.080.160.040.041.180.92
Total Assets18.5725.9518.5425.669.5512.45
Short Term Debt Incl. Current Port. of LT Debt0.440.430.410.391.380.36
Accounts Payable0.471.361.141.341.160.88
Other Current Liabilities4.243.582.872.901.691.49
Total Current Liabilities5.165.364.434.634.222.73
Long Term Debt0.240.360.480.580.690.79
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.38---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities5.405.725.285.224.913.52
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00143.62143.62
Common Equity13.1720.2213.2620.44-138.99-134.70
Total Shareholders Equity13.1720.2213.2620.444.648.93
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity13.1720.2213.2620.444.648.93
Total Liabilities & Stockholders Equity18.5725.9518.5425.669.5512.45
Book Value Per Share0.260.410.280.44-2.97-2.91
Tangible Book Value Per Share0.260.410.280.44-2.97-2.91
Full-Time Employees--99--90
Price to Book Ratio23.8325.7724.47-1.63-1.52-
Return on Assets-212.19-140.51----
Return on Equity-335.06-185.09----
Return on Invested Capital-55.78-34.17-53.83-37.67-86.84-55.33
Quick Ratio2.443.903.094.500.862.44
Current Ratio3.354.553.775.191.583.55

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-7.48-7.03-7.39-7.92-4.62-5.38
Depreciation0.160.150.150.140.140.14
Other Funds (Non Cash)0.590.330.190.330.020.15
Funds from Operations-6.73-6.55-7.05-7.45-4.46-5.09
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.670.49-0.631.78-0.070.10
Cash from Operating Activities-8.40-6.07-7.69-5.67-4.53-4.99
Capital Expenditures0.00-0.05-0.01-0.01-0.03-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.05-0.01-0.01-0.03-0.04
Cash Dividends Paid-0.010.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.4313.950.0123.390.170.03
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.4313.950.0123.390.170.03
Proceedsfrom Stock Options-0.5113.910.0023.370.000.00
Issuance or Reduction of Debt, Net0.000.000.00-1.001.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.4413.950.0122.391.170.03
Exchange Rate Effect-0.01-0.020.28-0.01-0.06-0.07
Net Change in Cash-8.867.82-7.4016.70-3.44-5.06
Free Cash Flow-8.40-6.11-7.69-5.68-4.56-5.03

Revenue breakdown

Electromedical & Electrotherapeutic Apparatus2024: 11.76M 2025: 13.55M
Non-US2024: 2.67M 2025: 2.90M
United States2024: 9.08M 2025: 10.66M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.25%2.0M26.9M164.17K
2026-10-158.11%2.2M26.9M156.57K
2026-09-307.82%2.1M26.9M166.77K
2026-09-156.60%1.9M28.8M152.13K
2026-08-316.73%1.9M28.0M144.96K
2026-08-146.39%1.8M28.0M147.33K
2026-07-316.86%1.9M27.9M146.53K
2026-07-157.19%2.1M29.4M155.53K
2026-06-306.24%1.7M27.5M152.47K
2026-06-155.35%1.5M27.5M251.33K
2026-05-294.91%1.4M27.5M266.69K
2026-05-155.13%1.4M27.5M288.22K
2026-04-305.19%1.4M27.5M309.74K
2026-04-154.92%1.4M27.5M368.67K
2026-03-314.08%1.2M30.5M437.67K
2026-03-131.93%0.6M28.6M305.86K
2026-02-271.43%0.4M28.6M374.56K
2026-02-131.50%0.4M28.6M342.45K
2026-01-301.25%0.4M28.6M312.69K
2026-01-150.33%0.1M28.6M236.42K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-04SCHEDULE 13G/ASEC
2026-09-288-KCurrent report2026-09-25SEC
2026-09-234/A2026-04-17SEC
2026-09-234/A2026-09-15SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-18424B5SEC
2026-09-188-KCurrent report2026-09-17SEC
2026-08-21EFFECTEffectiveness filing by commission orderSEC
2026-08-21424B5SEC
2026-08-188-KCurrent report2026-08-13SEC
2026-08-13S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-06-26SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-023Initial statement of beneficial ownership of securities2026-07-01SEC
2026-07-028-KCurrent report2026-07-01SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014/A2026-06-08SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-128-KCurrent report2026-06-11SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0915.00M200
2026-080000
2026-07906.10K200
2026-06101.81K100
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.3.79%
VANGUARD CAPITAL MANAGEMENT LLC2.12%
GEODE CAPITAL MANAGEMENT, LLC1.60%
STATE STREET CORP0.82%
VANGUARD PORTFOLIO MANAGEMENT LLC0.48%
NORTHERN TRUST CORP0.44%
UBS Group AG0.25%
VANGUARD FIDUCIARY TRUST CO0.21%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC0.16%
Bank of New York Mellon Corp0.14%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.85%
iShares Russell 2000 ETF1.65%
Fidelity Small Cap Index Fund0.76%
iShares Russell 2000 Growth ETF0.63%
VANGUARD RUSSELL 2000 INDEX FUND0.40%
iShares Micro-Cap ETF0.23%
VANGUARD EXTENDED MARKET INDEX FUND0.20%
Schwab Small-Cap Index Fund0.17%
Master Small Cap Index Series0.12%
Nuveen Small Cap Blend Index Fund0.09%

OakChart. CV. Cached 15 minutes.